

Microbiome Therapeutic Market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018-2025

The global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018-2025.

NEW YORK, NEW YORK, UNITED STATES, June 22, 2022

/EINPresswire.com/ -- The [Microbiome Therapeutic Market](#) is slated to grow on a decent note, i.e. witness a CAGR of 62.9% from 2018-2025, reaching US\$ 897.3 Mn by the year 2018-2025.

Workflows are getting streamlined due to increased connectivity and quicker internet. This is an era of medical IoT, which goes on to implement wearable devices and several other integrated applications for catering to healthcare needs. This would continue shortly as well.


According to the latest market report published by Persistence Market Research, titled 'Microbiome Therapeutics Market Potential: Global Pipeline Analysis and Assessment 2018 – 2025', the global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018-2025.

Get Free Sample Copy of this Report@

<https://www.persistencemarketresearch.com/samples/7990>

Persistence Market Research estimates that the global market for microbiome therapeutics is expected to be valued at US\$ 10.1 Mn in 2018 and is expected to reach US\$ 897.3 Mn by 2025 end. Need for reliable, precise and fast treatment options for certain diseases, such as C. difficile infection (CDI), phenylketonuria, hepatic encephalopathy and multidrug resistant urinary tract infection creates a huge potential for the growth of the microbiome therapeutics market.

Breakthrough therapy designation and orphan drug approvals for microbiome therapeutics is expected to accelerate the launch of developmental drugs in the microbiome therapeutics



market. A huge pipeline with over 120 candidates in different stages of development further creates the platform for potential growth of the microbiome therapeutics market.

Company Profiles:

Microbiome Therapeutics Inc.
SERES Therapeutics Inc.
LNC Therapeutics Inc.
Vedanta Biosciences Inc.
Enterome SA
Ferring B.V.
ViThera Pharmaceuticals Inc.
Second Genome Therapeutics
Rebiotix
Synlogic Inc.
4D Pharma Plc.
Ritter Pharmaceuticals
AvidBiotics
Osel Inc.
OxThera AB
Evelo Biosciences
AOBiome LLC
Immuron Ltd.

Request for Methodology@ <https://www.persistencemarketresearch.com/methodology/7990>

More Than 120 Drugs Are in the Pipeline in the Global Microbiome Therapeutics Market

At present there are no marketed microbiome therapeutics in the global market; however, the first drug is expected to be launched in 2018. The global market is dominated by over 25 companies with more than 120 drugs in the pipeline at different stages of development. However, over 60% of these drugs are in the discovery or preclinical phase, where there is high uncertainty surrounding the success of these molecules to reach the clinical phase and being launched as a new drug molecule. Majority of the pipeline drugs are being developed for gastrointestinal disorders and contribute approximately 28.7% of the total pipeline products.

Research and development in the microbiome industry is prominently dependent on government funding and research grants. Formation of policies and provision of subsidy by various governments encourages research and development activities across various segments of the research including discovery and clinical research. Government initiatives in funding microbiome research is the preliminary factor driving revenue growth of global microbiome therapeutics market. For instance, the U.S. government had allocated US\$ 1.6 Bn for microbiome R&D programs in 2016 & 2017.

Global Microbiome Therapeutics Market: Segmentation and Forecast

The market is segmented based on indication and region. On the basis of indication, the market has been segmented into type 2 diabetes, obesity, C. difficile infection and primary hyperoxyluria. C. difficile infection indication segment is expected to contribute the highest market share of over 34% by 2025 end. More number of product approvals for CDI is attributed to a high share of the C. difficile infection segment in the global market.

Human gut is home to over 100 Tn bacteria, containing thousands of different species. Long-term exposure to antibiotics causes dysbiosis in gut microbial composition, which leads to a variety of gastrointestinal disorders including CDI, ulcerative colitis, IBD, bacterial infection and even antibiotic associated diarrhea. Microbiome therapeutics however, present an excellent option for the treatment of CDI and other gastrointestinal disorders, as they are designed to naturally cure dysbiosis and bring the microbiome system back to normal functioning.

Access Full Report@ <https://www.persistencemarketresearch.com/checkout/7990>

Global Microbiome Therapeutics Market: Regional Forecast

On the basis of region, the market has been segmented into the U.S., Europe, Japan and Rest of the World (RoW). U.S. is estimated to contribute the highest share of over 44% by 2025 end, due to early launch of microbiome therapeutics and high penetration compared to other markets. The market in Japan is expected to witness delayed growth due to the complex regulatory pathways for new biological drugs. The microbiome therapeutics market in the rest of the world is expected to show gradual acceptance of “bug medicine”, Canada being the most lucrative among the rest of the world countries.

Global Microbiome Therapeutics Market: Competitive Landscape

Majority of the players in the microbiome therapeutics market are engaged in partnerships and collaborations with established pharmaceutical companies and academic institutes. Small start-up and clinical stage microbiome companies are capitalizing on venture financing to establish microbiome based novel therapeutics in the global market. Despite of decrease in the overall venture capital investments, the microbiome industry has witnessed high VC investments in 2016, and raised approximately to US\$ 336 Mn in 2016. Partnerships and research collaborations are another prominent trends identified in global microbiome therapeutics market.

Related Reports:

[Growth Factors Market](#) - As per Persistence Market Research's industry analysis, global demand for growth factors experienced year-on-year growth of 6.8% in 2020, with an estimated market value of around US\$ 1.8 Bn in 2021. NON-GMP grade holds a substantial share of over 71% in

the overall market.

[Autogenous Vaccines Market](#) - The global autogenous vaccines market is expected to progress at a healthy CAGR of 5.5% over the 2021-2031 assessment period, with demand being the highest from livestock farming companies.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes". The best possible returns are assured therein.

Contact Us:

Persistence Market Research

Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States

U.S. Ph. – +1-646-568-7751

USA-Canada Toll-free – +1 800-961-0353

Sales – sales@persistencemarketresearch.com

Website – <https://www.persistencemarketresearch.com>

Persistence Market Research Pvt. Ltd Atul Atul Singh

PMR

+1 646-568-7751

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/577934821>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.